Lozenge for treating sore throat, hoarseness and associated dry cough, and inflammatory diseases of the oral and pharyngeal cavity

Patent metadata

Field	Value
Publication number	US-10004774-B2
Application number	US-201615066604-A
Country	US
Kind code	B2
Filing date	Mar 10, 2016
Priority date	Apr 2, 2013
Publication date	Jun 26, 2018
Grant date	Jun 26, 2018

Abstract

The present invention relates to a pharmaceutical formulation containing a combination of (a) at least one astringent active substance and (b) at least one mucilaginous drug and the use thereof for the prevention or treatment of inflammatory diseases of the oropharyngeal region and for the treatment of painful irritations of the mucosa in the oropharyngeal region and associated irritable cough.

First claim

The invention claimed is:

1. A method for the treatment of inflammatory diseases of the oropharyngeal cavity which comprises the administration of a pharmaceutical composition in the form of a lozenge, the pharmaceutical composition comprising:
at least one astringent active substance comprising alum, wherein the astringent active substance is present in an amount of no greater than 10 mg and is further present in an amount of 0.1% to 1% by weight of the pharmaceutical composition; and
at least one mucilaginous drug comprising Icelandic moss, wherein the mucilaginous drug is present in an amount of 50 mg to 200 mg;
wherein a ratio by weight of Icelandic moss to alum is from 15:1 to 20:1.

2. The method according to claim 1 , wherein the condition to be treated includes irritable cough.

3. The method according to claim 1 , wherein the condition to be treated includes difficulty in swallowing.

4. The method according to claim 1 , wherein the condition to be treated includes hoarseness.

5. The method according to claim 1 , wherein the condition to be treated includes pain.

6. The method according to claim 1 , wherein the pharmaceutical composition, consists of (a) the at least one astringent active substance; (b) the at least one mucilaginous drug and (c) at least one further adjuvant.

7. The method according to claim 1 , wherein the astringent active substance is further selected from among tannin, policresulen and silver nitrate.

8. The method according to claim 7 , wherein the astringent active substance consists of alum.

Assignees

• Sanofi Aventis Deutschland

Inventors

• Boni Julia
• Plohmann Bernd
• Sauerland Sandra

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/351

  not condensed with another ring · CPC title

• A61P11/04

  for throat disorders · CPC title

• A61K31/7034

  attached to a carbocyclic compound, e.g. phloridzin · CPC title

• A61K33/06

  Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay} · CPC title